中医临床研究
中醫臨床研究
중의림상연구
CLINICAL JOURNAL OF CHINESE MEDICINE
2015年
1期
1-3,6
,共4页
宁心通脉包合物%气阴两虚血瘀痰郁型%冠心病%内皮素%一氧化氮
寧心通脈包閤物%氣陰兩虛血瘀痰鬱型%冠心病%內皮素%一氧化氮
저심통맥포합물%기음량허혈어담욱형%관심병%내피소%일양화담
The Ningxin Tongmai clathrate%Qiyin Liangxu Xueyu Tanyu type%Coronary heart disease%Plasma endothelin%Nitric oxide
目的：探讨宁心通脉包合物对冠心病患者血浆内皮素（ET）、一氧化氮（NO）水平的影响。方法：将128例冠心病患者随机分为治疗组及对照组，观察宁心通脉包合物对冠心病患者临床症状、心电图及血浆ET、NO水平的影响，并与硝酸异山梨醇（消心痛）对照组进行对比研究。结果：①宁心通脉包合物治疗组、硝酸异山梨醇对照组对冠心病心绞痛症状治疗的总有效率分别为86.1%、64.7%（P<0.05），宁心通脉包合物组优于对照组；②治疗组、对照组心电图好转总有效率分别为80.6%、58.8%（P<0.05），宁心通脉包合物组优于对照组；③治疗组治疗后血浆ET水平明显下降，差异有显著性意义（P<0.01），NO水平明显升高（P<0.05）。结论：宁心通脉包合物可降低患者血浆ET水平、升高NO水平，有一定保护冠心病患者内皮细胞功能的作用，并可改善临床症状，对治疗及预防冠心病等血管并发症有积极意义。
目的：探討寧心通脈包閤物對冠心病患者血漿內皮素（ET）、一氧化氮（NO）水平的影響。方法：將128例冠心病患者隨機分為治療組及對照組，觀察寧心通脈包閤物對冠心病患者臨床癥狀、心電圖及血漿ET、NO水平的影響，併與硝痠異山梨醇（消心痛）對照組進行對比研究。結果：①寧心通脈包閤物治療組、硝痠異山梨醇對照組對冠心病心絞痛癥狀治療的總有效率分彆為86.1%、64.7%（P<0.05），寧心通脈包閤物組優于對照組；②治療組、對照組心電圖好轉總有效率分彆為80.6%、58.8%（P<0.05），寧心通脈包閤物組優于對照組；③治療組治療後血漿ET水平明顯下降，差異有顯著性意義（P<0.01），NO水平明顯升高（P<0.05）。結論：寧心通脈包閤物可降低患者血漿ET水平、升高NO水平，有一定保護冠心病患者內皮細胞功能的作用，併可改善臨床癥狀，對治療及預防冠心病等血管併髮癥有積極意義。
목적：탐토저심통맥포합물대관심병환자혈장내피소（ET）、일양화담（NO）수평적영향。방법：장128례관심병환자수궤분위치료조급대조조，관찰저심통맥포합물대관심병환자림상증상、심전도급혈장ET、NO수평적영향，병여초산이산리순（소심통）대조조진행대비연구。결과：①저심통맥포합물치료조、초산이산리순대조조대관심병심교통증상치료적총유효솔분별위86.1%、64.7%（P<0.05），저심통맥포합물조우우대조조；②치료조、대조조심전도호전총유효솔분별위80.6%、58.8%（P<0.05），저심통맥포합물조우우대조조；③치료조치료후혈장ET수평명현하강，차이유현저성의의（P<0.01），NO수평명현승고（P<0.05）。결론：저심통맥포합물가강저환자혈장ET수평、승고NO수평，유일정보호관심병환자내피세포공능적작용，병가개선림상증상，대치료급예방관심병등혈관병발증유적겁의의。
Objective: To investigate clinical efficacy of the Ningxin Tongmai clathrate on plasma endothelin and nitric oxide levels in patients with coronary heart disease. Methods: 128 patients were randomly divided into the treatment group and the control group; clinical symptoms, electrocardiogram and plasma ET, NO levels were observed in the treatment group. The control group was given isosorbide dinitrate. Clinical efficacy in two groups was compared. Results: The total efficacy of angina pectoris symptoms in two groups was 86.1% and 64.7%,P<0.05, the treatment group was better; the total efficacy of ECG improvement in two groups was 80.6% and 58.8%, P<0.05, the treatment group was better; in treatment, ET level was obviously decreased after treatment, the difference was statistically significant (P<0.01), NO level was obviously improved after treatment. Conclusion: The Ningxin Tongmai clathrate could decrease ET level and improve NO level, protect endothelial function in patients with coronary heart disease, improve clinical symptoms and prevent vascular complications.
